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Abstract Trichosporon spp. has gained importance as the cases of immunosuppressed patients 
increase. The genus Trichosporon includes 6 species of clinical relevance that may cause 
supericial infections, such as white piedra and onychomycosis, or deep and invasive infections 
with high mortality rates. These microorganisms have a broad geographical distribution and 
some species are resistant to antifungal drugs in vitro. The present paper is a review on the 
virulence factors, associated infections, and in vitro susceptibility of the species with 
the highest incidence as pathogenic agents in humans.
1665-5796 © 2014 Revista Medicina Universitaria. Facultad de Medicina UANL. Publicado por Elsevier México. Todos 
los derechos reservados.
Introduction
Trichosporon spp. was first described by Beigel in 1865 
as the agent responsible for a benign hair infection called 
white piedra (meaning “stone” in Spanish). Beigel classi-
ied the microorganism as algae and placed it in the genus 
Pleurococcus. It wasn’t until 1890 when Behrend identiied 
the microorganism causing white piedra as a fungus which 
he called Trichosporon ovoides.1 Although generally associa-
ted with this superficial infection, Trichosporon spp. has 
gained importance as one of the most opportunistic syste-
mic infections since the irst case of invasive trichosporono-
sis involving the brain, reported in 1970.2
Trichosporon spp.
Trichosporon spp. belongs to the phylum Basidiomycota. It 
is a yeast-like fungus macroscopically characterized by for-
ming radially symmetrical colonies; these colonies may be 
white or yellowish, with a smooth texture, creamy, cere-
briform, powdery or moist. Microscopically, Trichosporon 
spp. forms hyaline septate hyphae, with abundant arthroco-
nidia and blastoconidia, and in some cases presents appre-
ssoria. Regarding physiological tests, they assimilate several 
carbohydrates and other carbon sources, yet they do not pos-
sess fermentation capabilities. A major characteristic of the 
Trichosporon spp. genus is their ability to hydrolize urea.1,3-5
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In 1902 Vuillemin grouped the species described for this 
genus under the Trichosporon beigelii denomination, a 
practice that remained until the late 90’s.5,6 Nevertheless, 
posterior classiications at morphological, biochemical, and 
molecular levels provided evidence of the existence of more 
than one species in the genus.
Approximately 50 species of the genus Trichosporon have 
been characterized, 16 of which are associated with disea-
ses in humans. Guého et al. (1994) typiied species that had 
displayed a major adaptation to the human body: T. asahii, 
T. asteroides, T. cutaneum, T. inkin, T. mucoides and T. 
ovoides. These 6 species, reclassiied from the Trichosporon 
beigelii taxon, remain the most relevant clinical species to 
date.7  
Virulence factors
There is little information regarding virulence factors pro-
duced by this microorganism.
Hemolysins, proteases, and lipases allow protein degrada-
tion and destabilization of the membranes of the host cell, 
increasing fungus pathogenicity. Dağ and Cerikçioğlu analy-
zed the production of proteases, phospholipases, and este-
rases of 48 T. asahii clinical isolates, and did not detect 
protease nor phospholipase activity in any of the isolates 
analyzed; however, all the evaluated strains displayed este-
rase activity.8 Similarly, Sun et al. evaluated protease, phos-
pholipase, and hemolysine production in 23 T. asahii clinical 
isolates, and  observed no protease nor phospholipase acti-
vity, yet 100% of isolates showed hemolysin activity. This 
activity, however, varied for the different T. asahii genoty-
pes identiied.9 It is important to underline that there are no 
reports about the production of lytic enzymes for Trichospo-
ron non-asahii species. 
Phenotypic switching is a fast and reversible change of 
colonial morphology and/or microscopic features. These 
changes may occur as a response to different environmental 
stimuli such as oxidative stress or lack of nutrients, or in-
trinsic factors such as a mutation in the deoxyribonucleic 
acid (DNA) repair systems.10 When phenotypic switching oc-
cur in vivo, they involve modiications in the expression of 
virulence factors, or alterations in the microorganism-host 
cell interactions, thus provoking an increment in the patho-
genicity and evasion of the immune response, as observed in 
Candida albicans and Cryptococcus neoformans.11-13 Lee et 
al., reported phenotypic switching in vitro for the irst time 
for T. beigelii. The isolated microorganism, recovered from 
a patient with a systemic infection, was capable of produ-
cing two different morphologies when cultivated at 30°C. 
Such morphotypes were accompanied by their respective 
structural microscopic changes. Thus, a rough, cerebriform, 
moist colony with irregular edges was accompanied micros-
copically by hyphae while a second powder morphotype, 
with a more regular topography and borders, showed mi-
croscopically a greater proportion of arthroconidia or blas-
toconidia.4 The phenotypic switching was also reported 
in vivo by Karashima et al., who performed experiments in-
volving repetitive inoculation of T. asahii in mice. They 
observed macro- and microscopic morphological differences 
when comparing the fungi before being inoculated and the 
same fungi recovered after 3 repetitive passages in 8-week-old 
ICR mice. Similar to the results obtained by Lee et al., Ka-
rashima observed that the rugged colony was accompanied 
microscopically by a greater proportion of hyphae, while a 
powdery colony was accompanied by a greater amount of 
conidia.14
In the same paper, Karashima et al. reported the produc-
tion of a cell wall component similar to the glucuronoxylo-
mannan (GXM) of C. neoformans. They observed that a 
larger amount of GXM was present in the recovered microor-
ganism after repeated inoculations in mice. GXM has been 
proposed to offer C. neoformans protection against phago-
cytosis by neutrophils and monocytes.14 
Another factor providing protection to the fungus is the 
formation of bioilms. Some microorganisms have the ability 
to produce an extracellular matrix, formed by polysacchari-
des, proteins, and DNA, which allow conglomeration of cells 
and their adherence to both organic and inorganic surfa-
ces.15 Due to the association of invasive infections to the use 
of catheters and similar devices, the microorganism’s ability 
to adhere itself and form a bioilm could play a very impor-
tant role in the pathogenesis during trichosporonosis. In 
2006, Di Bonaventura et al. assessed the bioilm growth ki-
netics in vitro for some clinical isolates of T. asahii. They 
found that T. asahii cells were capable of quickly adhering 
to polystyrene after incubation for 30 minutes, displaying a 
low metabolic activity during the irst 4 hours. The bioilm’s 
complexity increased after 6 to 8 hours of incubation, pe-
riod during which it was possible to observe a monolayer 
formed by filamentous structures. At 72 hours, the cells 
showed both yeast-like and filamentous structures em-
bedded in an extracellular matrix, forming a mature bioilm 
ranging from 20 to 40 µm in thickness. Biofilm formation 
was accompanied by a consequent increase in the resistan-
ce to voriconazole (up to 16,000 times more compared to 
planktonic cells).16 That same year, Dağ and Cerikçioğlu re-
ported a moderate to weak production of bioilms in 58% of 
the clinically isolated T. asahii species that were analyzed.8
Associated infections
Table 1 summarizes the main clinical manifestations and risk 
factors in infections caused by Trichosporon spp.
White piedra
White piedra is an infection in which white nodules are for-
med due to the aggregation of conidia around the hair shaft. 
These nodules are soft, whitish, have a deined border, and 
measure approximately between 1 and 3 mm of diameter. 
White piedra mainly affects capital hair; however, the in-
fection may present itself in the hair of armpits, pubis, and 
in a lesser degree moustaches and beards. It is a chronic 
and asymptomatic disease. It is a superficial infection in 
which fungi remain in contact with the cuticle, without in-
vading neither the hair medulla, scalp, nor skin.3
White piedra is a cosmopolitan and exogenous mycosis oc-
curring more frequently in tropical and temperate climates. 
Humidity and poor hygiene are among the risk factors for 
the attainment of this pathology. Women and children 
are the groups mainly affected by capital white piedra.17,18 
Most cases of genital white piedra, second in incidence, 
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involve males between 15 and 44 years of age.19,20 T. asahii, 
T. inkin, T. cutaneum, T. mucoides, and T. ovoides have all 
been associated with white piedra, T. ovoides being the one 
with the highest incidence.1,21  
Trichosporonosis
When Trichosporon spp. develops as an invasive infection, 
the disease is known as trichosporonosis. This infection has 
a mortality rate between 50% and 80%,22 and it is the second 
or third cause of fungemia in immunocompromised patients 
just after Candida spp.23-25 Trichosporonosis is considered an 
endogenous disease because the microorganism is com-
monly found as a part of the lora in the gastrointestinal 
tract, lungs, and skin.1,3
These opportunistic systemic infections have gained clini-
cal importance due to their growing prevalence in certain 
groups of patients. Neutropenia is the main risk factor. A 
relationship between trichosporonosis and having undergo-
ne an invasive clinical procedure (e.g., probes and cathe-
ters) has been established as well.
Kontoyannis et al. (2004) evaluated risk factors associated 
with the infection caused by Trichosporon spp. in 17 cancer 
patients. They observed that out of the 10 patients who dis-
played fungemia, 41% developed trichosporonosis subse-
quent to the use of catheters. The underlying disease in 
most patients was acute leukemia, and in 65% of the cases 
neutropenia was observed. Some patients had received che-
motherapy (76%) or high doses of corticosteroids (89%) 
1 month prior to the trichosporonosis diagnosis.26 Girmenia 
et al. (2005) performed a retrospective study including 287 
cases of trichosporonosis worldwide. They found that 62.8% 
of the patients had suffered from a hematologic disease 
previous to the trichosporonosis diagnosis. Acute leukemia 
had the highest incidence (68%). Other conditions of risk 
associated with the development of trichosporonosis were 
solid tumors, transplants, peritoneal dialysis, and human 
immunodeficiency virus.27 Ruan et al. (2009), based on a 
study of 19 cases of invasive trichosporonosis, reported the 
use of central catheters as the main risk factor (90%).22 Su-
zuki et al. (2010) analyzed 33 patients with hematological 
diseases; the results were similar to the ones previously re-
ported: acute leukemia (82%) and neutropenia (85%) were 
the main risk factors for trichosporonosis. Moreover, it was 
observed that most patients were undergoing  chemothera-
py when diagnosed with this mycosis.28
The main trichosporonosis manifestations are fever and 
fungemia. However, tissue invasion may develop. Cases of 
inlammation and abscesses in different organs and tissues 
(heart, brain, liver, spleen, esophagus, urinary tract, joints, 
peritoneum) have been reported. T. asahii, T. asteroides, T. 
cutaneum, T. inkin and T. mucoides are the 5 most common 
species associated with trichosporonosis cases.9,22,29-32
Tissue invasion and damage
There are reports using murine models for evaluating tissue 
damage in invassive infections by Trichosporon spp.. Mice 
require cyclophosphamide-induced immunosuppression 
prior to high doses of fungi inoculation, which emulates the 
neutropenia in patients who develop trichosporonosis. 
Studies in animal survival have proven that the establish-
ment of the infection is dose dependent. However, both the 
inoculum size causing mortality and time elapsed until tis-
sue invasion is detected vary in different reports. Gokaslan 
and Anaissie determined that an inoculum of ≥ 2 x 107 colony 
forming units (CFU) causes 100% mortality and invasion of 
organs in immunosupressed mice 6 days after infection.34 On 
the other hand, Hospenthal et al. reported that an inoculum 
of ≥ 7 x 106 CFU caused 100% mortality with tissue invasion 6 
hours after infection.35 These models were developed with 
infection by T. beigelii, therefore the observed differen- 
ces in infectivity and progress of the disease could be a re-
sult of an induced infection by an unidentiied species of the 
genus Trichosporon. Yamagata et al. utilized an inocu- 
lum of 3 x 106 CFU of T. asahii in a model in which mice were 
Table 1 Infections caused by Trichosporon spp., main clinical manifestations and risk factors.
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immunosuppressed at week 1, showing a signiicant diffe-
rence compared to the animals which were not immunosup-
pressed or those receiving a second cyclophosphamide dose 
at week 3 (20% of mortality). They concluded that the irst 3 
weeks are critical for the development of systemic trichos-
poronosis by T. asahii.29
Fungi presence in the affected organs is generalized. Per-
sistence of the microorganism in kidneys of immunosuppres-
sed mice as well as of immunocompetent ones has been 
reported. In animal groups where mortality is induced via 
inoculation of lethal doses, the initial inoculum has been 
recovered as much as 36-fold from brain, heart and kidney. 
A resolution of the infection in re-immunosuppressed ani-
mals has not been observed. The presence of Trichosporon 
spp. has been conirmed by molecular methods, even when 
the cell count is under the detection limits.29,34,35
Hyphae and conidia have been observed in different pro-
portions depending on the organ and the stage of infection. 
Yeast-like structures are often found in earlier stages, while 
hyphae and arthroconidia are present in later stages of the 
infection. Predominance of yeast-like structures in the lungs 
of the infected animals has been reported.35 
One of the most prevalent signs of invasive trichosporono-
sis is the granulomatous inlammation reported in lungs, li-
ver, lymph nodes, and spleen in immunosuppressed and 
immunecompetent mice, as well as a fungal invasion of the 
blood vessels’ lumen or periphery.34-36
Other indings include kidney, spleen, lung, and heart hy-
peremia. Tubular edema, focal parenchymal destruction, 
cortical tubular necrosis, and chronic inlammation with i-
brosis have been observed in the kidneys of mice surviving 
infection. In the liver, hepatic sinus dilation and congestion 
have been reported, as well as degeneration and necrosis of 
some hepatocytes and proliferation of Kupffer cells. Splenic 
sinuses dilation and splenomegaly have also been observed. 
In lungs, edema, hemorrhage, and alveolar ectasia have 
been described. In the heart, evidence of hemorrhage and 
cardiomyocytes necrosis have been reported. 34-37
Onychomycosis
In the last few years, cases of onychomycosis associated 
with infections caused by Trichosporon spp. have increased. 
Around the world, this genus is the agent responsible for 
1.3% to 10% of onychomycosis cases, being T. asahii, T. mu-
coides, and T. inkin the most frequently involved microorga-
nisms.38-40 There have been discrepancies between cases 
reported in Mexico and other countries. In a study perfor-
med in pediatric patients from a rural area, Archer-Dubon 
et al. isolated T. cutaneum in 42% of the patients with 
onychomycosis and athlete’s foot, a percentage higher than 
the estimated for infections by dermatophytes and Candida 
spp., microorganisms typically responsible for foot infec-
tions.41 
Laboratory diagnosis 
Clinical laboratory diagnosis varies in cases of supericial 
and systemic infections. In the case of white piedra, the 
hair sample is submerged in a potassium hydroxide solution 
for observation under the microscope of the nodules formed 
by the aggregated spores around the hair shaft, which 
allows differential diagnosis of other parasitizations such as 
pediculosis or trichomycosis. Similarly, onychomycosis diag-
nosis requires the nail scrape to be submerged in pota- 
ssium hydroxide for microscopic observation of conidia and 
hyphae. In both cases, precise etiologic diagnosis requires a 
culture. Trichosporonosis diagnosis is made routinely by the 
recovery of fungi from blood and/or biopsies.3
Cultures obtained from diverse clinical samples are used 
for identifying the etiologic agent through its microscopic 
morphology by conirming the presence of the 3 characteris-
tic structures of the genus Trichosporon: hyphae, arthrocon-
dia, and blastocondia. The biochemical profile may be 
obtained by auxanography, which evaluates the ability to 
assimilate different sources of carbon. However, the com-
plete biochemical characterization of species of the genus 
Trichosporon is based on the assimilation of approximately 
50 carbon compounds and requires anywhere between 5 and 
15 days for the readings; consequently, it is not practical to 
carry out this battery of tests for the precise identiication 
of pathogenic species. There are commercial methods 
which systematize the application of assimilation tests and 
reduce the required identiication time. The API 20C AUX 
system by bioMérieux is a commercial micromethod, which 
has turned into the most used in clinical laboratories. This 
system evaluates the assimilation ability of 19 carbohydra-
tes and allows identiication within a timeframe of 24 to 72 
hours of incubation. However, a limitation of this test is that 
it only allows the identiication of 3 species of the genus: T. 
asahii, T. inkin, and T. mucoides. This last characteristic 
prevents its generalized use.
Different molecular methods have been developed as fast 
and effective alternatives for the precise identiication of 
many pathogens at the species level. Ribosomal DNA is wi-
dely used in the systematic identification of microor- 
ganisms. Molecular identiication of fungi is typically perfor-
med by sequencing of the internal transcribed spacer (ITS) 
region. One of the inconveniences of this region is the fact 
that it is highly homologous between the different species 
in the genus Trichosporon; therefore, the analysis of other 
genes or regions with higher heterology is needed in or- 
der to obtain a more accurate identiication. Sugita et al. 
analyzed 84 strains corresponding to 25 species of the genus 
Trichosporon to evaluate the eficacy of sequencing the ITS 
region and the intergenic spacer 1 (IGS1) region for the pre-
cise identiication at a species level. They found a higher 
heterology between IGS1 regions in comparison to ITS. This 
makes the IGS1 sequencing analysis superior compared to 
ITS for the differentiation between species of the genus. In 
addition, this method allows genotypiication.42 
A growing number of reports reveal the effectiveness of 
molecular methods in the identiication of this microorga-
nism. These publications show the lack of speciicity of the 
conventional identiication methods based in morphologic 
and biochemical criteria.43-46 
Treatment
Supericial infections caused by Trichosporon spp. may be 
treated with galenic solutions such as 1% mercuric chlori-
de, 1% iodine solution, and 30% salicylic acid. They may be 
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treated with topical antifungals, mainly imidazoles like eco-
nazole, isoconazole, miconazole, and ketoconazole. In pa-
tients with white piedra, the trimming or shaving of 
parasitized hairs or affected areas prior to topical treatment 
is recommended.1,3,17
Management of deep infections has been a bigger challen-
ge. Trichosporon spp. has displayed variable resistance to 
the most common antifungal treatments; consequently, the-
re is no optimal treatment for trichosporonosis cases.
In vitro susceptibility
Trichosporon spp. was irst reported as an amphotericin B-
resistant pathogen by Walsh et al. in 1990, after evaluating 
2 T. beigelii isolates obtained from patients with systemic 
infections.47 Since its taxonomic revision, several studies 
have assessed the eficacy of different antifungals against 
the species of the genus, mainly T. asahii.
It is important to mention that to this day there is not an 
established method to determine in vitro susceptibility of 
species belonging to the genus Trichosporon. The most widely 
used protocol is an adaptation of the method used for Candi-
da spp. and C. neoformans described in documents M27 and 
M44 of the Clinical and Laboratory Standards Institute.
One of the most evaluated antifungals has been amphote-
ricin B (AMB).  This is a polyenic derivate that destabilizes 
the fungal cytoplasmic membrane; it is the treatment of 
choice for systemic infections. The resistance of Trichospo-
ron spp. to AMB has been reported. T. asahii consistently 
exhibits a MIC of  ≥ 2 µg/mL (Minimal Inhibitory Concen-
tration, which prevents visible growth of 90% of isola-
tes).22,44,48,49 There are similar MICs for other clinical isolates 
including T. asteroides, T. cutaneum, and T. ovoides.22 Rodrí-
guez-Tudela et al. (2005), contrary to the previous study, 
reported low MICs for T. cutaneum (0.25-0.5 µg/ml) and T. 
ovoides (0.37 µg/ml). T. mucoides showed great variability 
regarding susceptibility to AMB, with MICs ranging between 
0.015 and 16.0 µg/ml.44 T. inkin is the species which has 
displayed greater in vitro susceptibility to the inhibitory ac-
tivity of AMB, with MICs from 0.14 to 1.0 µg/ml.44,48
Triazolic compounds are inhibitors of the ergosterol 
synthesis, the main component of the fungal cytoplasmic 
membrane. In addition, they interact with enzymes at a mi-
tochondrial level causing the accumulation of free radicals 
inside the cell and provoking the inhibition of fungal growth. 
Triazolics include fluconazole (FLC), voriconazole (VRC), 
itraconazole (ITR), and posaconazole (POS). These agents 
have displayed better in vitro activity against Trichosporon 
spp., with relatively low MICs for T. asahii (FLC 1.27 to ≤ 
10.3 µg/ml, ITR ≤ 1.4 µg/ml, POS 0.25 µg/ml), T. asteroides 
(FLC 0.8 µg/ml, ITR 0.06 µg/ml), T. inkin (FLC ≤ 4 µg/ml, 
ITR ≤ 1 µg/ml), T. cutaneum (FLC ≤ 32 µg/ml, ITR ≤ 1 µg/
ml), and T. ovoides (FLC 1.74 µg/ml, ITR 0.1 µg/ml).22,44,48,49 
Voriconazole is particularly effective for fungal inhibition in 
vitro, with MICs of ≤ 0.28 µg/ml for the 6 more frequently 
isolated Trichosporon species causing human pathology.44,49
Terbinaine (TER) is a synthetic antifungal derived from 
allylamines that inhibits ergosterol synthesis. TER requires 
high concentrations in order to inhibit T. asahii (12.6 µg/
ml), as opposed to the inhibition of T. cutaneum o T. inkin (1 
µg/ml).48
5-Flucytosine (5-FC) is an inhibitor of the synthesis of nu-
cleic acids; it interacts with the fungal RNA disrupting the 
synthesis of proteins. 5-FC has shown poor antifungal activi-
ty against the most clinically relevant species, with MICs ≥ 2 
µg/ml and reaching concentrations of up to 128 µg/ml for T. 
mucoides.9,22,44,49
Caspofungin (CAS) is an echinocandin that inhibits the 
synthesis of the fungal cell wall. CAS MICs are high for T. 
asahii (≥ 4 µg/ml) and T. asteroides (16 µg/ml).49,50
Immunotherapy 
Since neutropenia is the main condition associated with the 
development of trichosporonosis, the use of cytokines has 
been considered for the treatment of these infections. 
Some of the factors used are the granulocytes colony stimu-
lating factors (G-CSF), which increase polymorphonuclear 
cell count, and the granulocytes-macrophages colony stimu-
lating factors (GM-CSF), which activate monocytes and ma-
crophages functions. Muranka et al. (1997) used a murine 
model with disseminated T. asahii trichosporonosis for the 
evaluation of G-CSF and GM-CSF as therapy against systemic 
infection. They observed that the use of G-CSF prior to 
fungal infection increased the survival in mice from 25% 
to 100%, decreasing the fungal load and tissue damage in 
affected organs, with the most notable improvement in the 
lungs. The increase in neutrophils by GM-CSF was lower than 
the one caused by G-CSF, so the use of GM-CSF therapy did 
not generate any major improvements in animals. In the 
same study, they observed an increase of tumor necrosis 
factor alpha (TNF-α) in bronchoalveolar lavage luid in mice 
infected with lethal doses of T. asahii and treated with GM-
CSF compared to non-immunosuppressed animals or animals 
treated with G-CSF. In addition, a negative correlation bet-
ween TNF-α production and the presence of leukocytes in 
peripheral blood was observed, decreasing as mice recupe-
rated from the neutropenia. Anti-TNF-α therapy did not fa-
vor infection resolution. The investigators concluded that 
neutrophil count was the most critical factor in the develo-
pment of trichosporonosis; however, other factors, such as 
TNF-α in lung, played an important role in the resolution of 
the infection.51
Similarly, the use of macrophages colony stimulating factor 
(M-CSF) has been evaluated as an activator of phagocytosis in 
a trichosporonosis murine model with T. asahii. M-CSF increa-
sed fungicidal activity in mononuclear cells, with a notable 
increase in survival and a decrease in fungal load. In addition, 
an increase in TNF-α in lungs and plasma in animals treated 
with M-CSF was noticeable. Different from the results repor-
ted by Muranaka et al., anti-TNF-α treatment did increase 
survival in mice. Results showed how M-CSF exponentially in-
creased fungal activity by mononuclear phagocytes, helped 
partly by the production of TNF-α.52 
Similar results regarding the effect of G-CSF, GM-CSG, and 
M-CSF on leukocytes and their role in trichosporonosis reso-
lution were reported by Roilides et al. (2002).53
Conclusion 
Vast distribution, antifungal resistance, and an increase in 
the number of patients presenting risk factors have made 
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relevant the study of species belonging to the genus Trichos-
poron as opportunistic fungal agents relevant. High mortali-
ty rates in patients with systemic infections as well as a lack 
of an optimal treatment generate the need to increase the 
knowledge of this particular pathogen, in a way that allows 
us to understand its virulence mechanisms, and conse-
quently, to obtain the necessary tools for the development 
of effective therapies against these microorganisms. 
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